CGTLive’s Weekly Rewind – February 24, 2023

Article

Review top news and interview highlights from the week ending February 24, 2023.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Arsa-cel Shows Favorable Risk/Benefit Profile in up to 11 Years of Follow-up Data

Long term data from 2 clinical trials and expanded access programs were presented at WORLDSymposium 2023.

2. Brian Van Tine, MD, PhD, on Bringing Cell Therapy Into Synovial Sarcoma Treatment

The professor medicine and pediatrics at Washington University in St. Louis overviewed data from the SPEARHEAD-1 trial of afami-cel.

3. HSC Gene Therapy Demonstrates Improvements in Type 3 Gaucher Disease Case Study

The patient has not re-started any of his previous Gaucher-specific therapy since receiving AVR-RD-02.

4. Everett Meyer, MD, PhD, on Reducing GvHD in Leukemia Treatment

The assistant professor of medicine and pediatrics at Stanford University discussed updated data from 2 studies of Orca-T cell therapy.

5. Graphite Bio Drops Lead Sickle Cell Gene-Edited Cell Therapy

The announcement of a “strategic realignment” comes less than 2 months after the company voluntarily paused the CEDAR clinical trial due to a serious, nula-cel-related adverse event.

Related Videos
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Maria Escolar, MD, the chief medical officer of Forge Biologics
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma
Francesca Del Bufalo, MD, PhD, a medical doctor and scientist at Bambino Gesù Chidren’s Hospital
Carlos Ramos, MD, on Alternatives to T-Cell Therapy
© 2024 MJH Life Sciences

All rights reserved.